胆道恶性肿瘤（Biliary Tract Cancer, BTC）是一种复杂且高度异质性的消化系统肿瘤，其主要病理组织类型以腺癌为主。根据其解剖位置的不同，胆道恶性肿瘤可以分为肝内胆道癌（Intrahepatic Cholangiocarcinoma, iCCA）、肝门部胆管癌（Perihilar Cholangiocarcinoma, pCCA）、远端胆管癌（Distal ...

编者按：岁月匆匆，一年的时光转瞬即逝，我们站在时间的交汇点上，回首往昔。在过去的一年里，胆道恶性肿瘤（BTC）领域的研究取得了诸多可喜进展，本刊特邀请解放军总医院第五医学中心陆荫英教授对其进行盘点总结。在2024年BTC领域的多项关键临床研究中，TO ...

Biliary tract disease describes any disease that affects the biliary tract the gall bladder, bile ducts and accompanying structures. Examples include primary sclerosing cholangitis, secondary ...

Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers with FGFR2 gene fusion ...

Top-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with biliary tract cancer (BTC) is on ...

Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the drug. Tasfygo (tasurgratinib succinate; formerly E7090), a small-molecule ...

Compass Therapeutics (CMPX) announced a corporate and financial update. Top-line Phase 2/3 data readout for CTX-009, now named tovecimig, in ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...